Five details:
1. Veritas and Elliott are aiming for Athenahealth to be valued at more than $20 billion in a transaction, people familiar with the matter told Bloomberg.
2. The firms are working with Goldman Sachs Group and Evercore to explore options for the EHR company, and the bankers have contacted about a half-dozen potential buyers to see their interest.
3. Veritas and Elliott hope to complete a deal for Athenahealth by the end of the first quarter of 2022. However, the firms haven’t made a decision yet and could choose to keep the EHR company, the people familiar with the matter said.
4. Veritas and Elliott completed their acquisition of Athenahealth in February 2019 for $5.7 billion. As a result of the sale’s completion, shares of Athenahealth’s common stock were removed from Nasdaq, and trading was suspended.
5. Athenahealth declined Bloomberg and Becker‘s comment requests.
Editor’s note: This article was updated Sept. 25 at 12:00 p.m. CT.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
